LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer by Romanuik, Tammy L et al.
RESEARCH ARTICLE Open Access
LNCaP Atlas: Gene expression associated with
in vivo progression to castration-recurrent
prostate cancer
Tammy L Romanuik, Gang Wang, Olena Morozova, Allen Delaney, Marco A Marra, Marianne D Sadar
*
Abstract
Background: There is no cure for castration-recurrent prostate cancer (CRPC) and the mechanisms underlying this
stage of the disease are unknown.
Methods: We analyzed the transcriptome of human LNCaP prostate cancer cells as they progress to CRPC in vivo
using replicate LongSAGE libraries. We refer to these libraries as the LNCaP atlas and compared these gene
expression profiles with current suggested models of CRPC.
Results: Three million tags were sequenced using in vivo samples at various stages of hormonal progression to
reveal 96 novel genes differentially expressed in CRPC. Thirty-one genes encode proteins that are either secreted or
are located at the plasma membrane, 21 genes changed levels of expression in response to androgen, and 8
genes have enriched expression in the prostate. Expression of 26, 6, 12, and 15 genes have previously been linked
to prostate cancer, Gleason grade, progression, and metastasis, respectively. Expression profiles of genes in CRPC
support a role for the transcriptional activity of the androgen receptor (CCNH, CUEDC2, FLNA, PSMA7), steroid
synthesis and metabolism (DHCR24, DHRS7, ELOVL5, HSD17B4, OPRK1), neuroendocrine (ENO2, MAOA, OPRK1,
S100A10, TRPM8), and proliferation (GAS5, GNB2L1, MT-ND3, NKX3-1, PCGEM1, PTGFR, STEAP1, TMEM30A), but neither
supported nor discounted a role for cell survival genes.
Conclusions: The in vivo gene expression atlas for LNCaP was sequenced and support a role for the androgen
receptor in CRPC.
Background
Systemic androgen-deprivation therapy by orchiectomy
or agonists of gonadotropic releasing hormone are routi-
nely used to treat men with metastatic prostate cancer
to reduce tumor burden and pain. This therapy is based
on the dependency of prostate cells for androgens to
grow and survive. The inability of androgen-deprivation
therapy to completely and effectively eliminate all meta-
static prostate cancer cell populations is manifested by a
predictable and inevitable relapse, referred to as castra-
tion-recurrent prostate cancer (CRPC). CRPC is the end
stage of the disease and fatal to the patient within 16-18
months of onset.
The mechanisms underlying progression to CRPC are
unknown. However, there are several models to explain
its development. One such model indicates the involve-
ment of the androgen signaling pathway [1-4]. Key to
this pathway is the androgen receptor (AR) which is a
steroid hormone receptor and transcription factor.
Mechanisms of progression to CRPC that involve or uti-
lize the androgen signaling pathway include: hypersensi-
tivity due to AR gene amplification [5,6]; changes in AR
co-regulators such as nuclear receptor coactivators
(NCOA1 and NCOA2) [7,8]; intraprostatic de novo
synthesis of androgen [9] or metabolism of AR ligands
from residual adrenal androgens [10,11]; AR promiscuity
of ligand specificity due to mutations [12]; and ligand-
independent activation of AR by growth factors [protein
kinase A (PKA), interleukin 6 (IL6), and epidermal
growth factor (EGF)] [13-15]. Activation of the AR can
be determined by assaying for the expression of target
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models of CRPC include the neuroendocrine differentia-
tion [17], the stem cell model [18] and the imbalance
between cell growth and cell death [3]. It is conceivable
that these models may not mutual exclusive. For exam-
ple altered AR activity may impact cell survival and
proliferation.
Here, we describe long serial analysis of gene expres-
sion (LongSAGE) libraries [19,20] made from RNA
sampled from biological replicates of the in vivo LNCaP
Hollow Fiber model of prostate cancer as it progresses
to the castration-recurrent stage. Gene expression signa-
tures that were consistent among the replicate libraries
were applied to the current models of CRPC.
Methods
In vivo LNCaP Hollow Fiber model
The LNCaP Hollow Fiber model of prostate cancer was
performed as described previously [21-23]. All animal
experiments were performed according to a protocol
approved by the Committee on Animal Care of the
University of British Columbia. Serum PSA levels
were determined by enzymatic immunoassay kit (Abbott
Laboratories, Abbott Park, IL, USA). Fibers were removed
on three separate occasions representing different stages
of hormonal progression that were androgen-sensitive
(AS), responsive to androgen-deprivation (RAD), and
castration-recurrent (CR). Samples were retrieved immedi-
ately prior to castration (AS), as well as 10 (RAD) and
72 days (CR) post-surgical castration.
RNA sample generation, processing, and quality control
Total RNA was isolated immediately from cells
harvested from the in vivo Hollow Fiber model using
TRIZOL Reagent (Invitrogen) following the manufac-
turer’s instructions. Genomic DNA was removed from
RNA samples with DNaseI (Invitrogen). RNA quality
and quantity were assessed by the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Mississauga, ON, Canada)
and RNA 6000 Nano LabChip kit (Caliper Technologies,
Hopkinton, MA, USA).
Quantitative real-time polymerase chain reaction
Oligo-d(T)-primed total RNAs (0.5 μg per sample) were
reverse-transcribed with SuperScript III (Invitrogen Life
Technologies, Carlsbad, CA, USA). An appropriate dilu-
tion of cDNA and gene-specific primers were combined
with SYBR Green Supermix (Invitrogen) and amplified in
ABI 7900 real-time PCR machine (Applied Biosystems,
F o s t e rC i t y ,C A ,U S A ) .A l lq P C Rr e a c t i o n sw e r ep e r -
formed in triplicate. The threshold cycle number (Ct)
and expression values with standard deviations were calcu-
lated in Excel. Primer sequences for real-time PCRs are:
KLK3,F ’:5 ’-CCAAGTTCATGCTGTGTGCT-3’ and
R:’ 5’-CCCATGACGTGATACCTTGA-3’; glyceraldehyde-
3-phosphate (GAPDH), F’:5 ’-CTGACTTCAACAGCGA-
CACC-3’ and R:’ 5’-TGCTGTAGCCAAATTCGTTG-3’).
Real-time amplification was performed with initial dena-
turation at 95°C for 2 min, followed by 40 cycles of two-
step amplification (95°C for 15 sec, 55°C for 30 sec).
LongSAGE library production and sequencing
RNA from the hollow fibers of three mice (biological
replicates) representing different stages of prostate cancer
progression (AS, RAD, and CR) were used to make a
total of nine LongSAGE libraries. LongSAGE libraries
were constructed and sequenced at the Genome Sciences
Centre, British Columbia Cancer Agency. Five micro-
grams of starting total RNA was used in conjunction
with the Invitrogen I-SAGE Long kit and protocol with
alterations [24]. Raw LongSAGE data are available at
Gene Expression Omnibus [25] as series accession num-
ber GSE18402. Individual sample accession numbers are
as follows: S1885, GSM458902; S1886, GSM458903;
S1887, GSM458904; S1888, GSM458905; S1889,
GSM458906; S1890, GSM458907; S1891, GSM458908;
S1892, GSM458909; and S1893, GSM458910.
Gene expression analysis
LongSAGE expression data was analyzed with Disco-
verySpace 4.01 software [26]. Sequence data were fil-
tered for bad tags (tags with one N-base call) and
linker-derived tags (artifact tags). Only LongSAGE tags
w i t has e q u e n c eq u a l i t yf a c t o r( Q F )g r e a t e rt h a n9 5 %
were included in analysis. The phylogenetic tree was
constructed with a distance metric of 1-r (where “r”
equals the Pearson correlation coefficient). Correlations
were computed (including tag counts of zero) using the
Regress program of the Stat package written by Ron
Perlman, and the tree was optimized using the Fitch
program [27] in the Phylip package [28]. Graphics were
produced from the tree files using the program Tree-
View [29]. Tag clustering analysis was performed using
the Poisson distribution-based K-means clustering algo-
rithm. The K-means algorithm clusters tags based on
count into ‘K’ partitions, with the minimum intracluster
variance. PoissonC was developed specifically for the
analysis of SAGE data [30]. The java implementation
of the algorithm was kindly provided by Dr. Li Cai
(Rutgers University, NJ, USA). An optimal value for K
(K = 10) was determined [31].
Principle component analysis
Principle component analysis was performed using
GeneSpring™ software version 7.2 (Silicon Genetics,
CA). Affymetrix datasets of clinical prostate cancer
and normal tissue were downloaded from Gene Expres-
sion Omnibus [25] (accession numbers: GDS1439 and
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novel CR-associated genes, 76 genes had corresponding
Affymetrix probe sets. These probe sets were applied as
the gene signature in this analysis. Principle component
(PC) scores were calculated according to the standard
correlation between each condition vector and each
principle component vector.
Results
LongSAGE library and tag clustering
RNA isolated from the LNCaP Hollow Fiber model was
obtained from at least three different mice (13N, 15N,
and 13R; biological replicates) at three stages of cancer
progression that were androgen-sensitive (AS), respon-
sive to androgen-deprivation (RAD), and castration-
recurrent (CR). To confirm that the samples represented
unique disease-states, we determined the levels of KLK3
mRNA, a biomarker that correlates with progression,
using quantitative real time-polymerase chain reaction
(qRT-PCR). As expected, KLK3 mRNA levels dropped
in the stage of cancer progression that was RAD versus
AS (58%, 49%, and 37%), and rose in the stage of cancer
progression that was CR versus RAD (229%, 349%, and
264%) for mice 13R, 15N, and 13N, respectively (Addi-
tional file 1). Therefore, we constructed nine LongSAGE
libraries, one for each stage and replicate.
LongSAGE libraries were sequenced to 310,072 -
339,864 tags each, with a combined total of 2,931,124
tags, and filtered to leave only useful tags for analysis
(Table 1). First, bad tags were removed because they
contain at least one N-base call in the LongSAGE tag
sequence. The sequencing of the LongSAGE libraries
was base called using PHRED software. Tag sequence-
quality factor (QF) and probability was calculated to
ascertain which tags contain erroneous base-calls. The
second line of filtering removed LongSAGE tags with
probabilities less than 0.95 (QF < 95%). Linkers were
introduced into SAGE libraries as known sequences uti-
lized to amplify ditags prior to concatenation. At a low
frequency, linkers ligate to themselves creating linker-
derived tags (LDTs). These LDTs do not represent tran-
scripts and were removed from the LongSAGE libraries.
A total of 2,305,589 useful tags represented by 263,197
tag types remained after filtering. Data analysis was
carried out on this filtered data.
The LongSAGE libraries were hierarchically clustered
and displayed as a phylogenetic tree. In most cases,
LongSAGE libraries made from the same disease stage
(AS, RAD, or CR) clustered together more closely than
LongSAGE libraries made from the same biological
replicate (mice 13N, 15N, or 13R; Figure 1). This sug-
gests the captured transcriptomes were representative of
disease stage with minimal influence from biological
variation.
Identification of groups of genes that behave similarly
during progression of prostate cancer was conducted
through K-means clustering of tags using the PoissonC
algorithm [30]. For each biological replicate (mice 13N,
15N, or 13R), all tag types were clustered that had a
combined count greater than ten in the three libraries
representing disease stages (AS, RAD, and CR) and
mapped unambiguously sense to a transcript in refer-
ence sequence (RefSeq; February 28
th, 2008) [32] using
DiscoverySpace4 software [33]. By plotting within clus-
ter dispersion (i.e., intracluster variance) against a range
of K (number of clusters; Additional file 1, Figure S2),
we determined that ten clusters best embodied the
expression patterns present in each biological replicate.
This was decided based on the inflection point in the
graph (Additional file 1, Figure S2), showing that after
reaching K = 10, increasing the number of K did not
substantially reduce the within cluster dispersion.
K-means clustering was performed over 100 iterations,
so that tags would be placed in clusters that best repre-
sent their expression trend. The most common clusters
for each tag are displayed (Figure 2). In only three
instances, there were similar clusters in just two of the
three biological replicates. Consequently, consistent
changes in gene expression during progression were
represented in 11 patterns. Differences among expres-
sion patterns for each biological replicate may be
explained by biological variation, the probability of sam-
pling a given LongSAGE tag, and/or imperfections in
K-means clustering (e.g, variance may not be a good
measure of cluster scatter).
Gene ontology enrichment analysis
We conducted Gene Ontology (GO) [34] enrichment ana-
lysis using Expression Analysis Systematic Explorer (EASE)
[35] software to determine whether specific GO annota-
tions were over-represented in the K-means clusters.
Enrichment was defined by the EASE score (p-value ≤
0.05) generated during comparison to all the other clusters
in the biological replicate. This analysis was done for each
biological replicate (3 mice: 13N, 15N, or 13R).
To enable visual differences between the 11 expression
trends, the clusters were amalgamated into five major
trends: group 1, up during progression; group 2, down
during progression; group 3, peak in the RAD stage; group
4, constant during progression; and group 5, valley in
RAD stage (Figure 2). To be consistent, the GO enrich-
ment data was combined into five major trends which
resulted in redundancy in GO terms. To simplify the GO
enrichment data, similar terms were pooled into represen-
tative categories. Categorical gene ontology enrichments
of the five major expression trends are shown in Figure 3.
These data indicate that steroid binding, heat shock pro-
tein activity, de-phosphorylation activity, and glycolysis all
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in the stage that was CR. Interestingly, steroid hormone
receptor activity continues to increase throughout progres-
sion. Both of these expression trends were observed for
genes with GO terms for transcription factor activity or
secretion. The GO categories for genes with kinase activity
and signal transduction displayed expression trends with
peaks and valleys at the stage that was RAD. The levels of
expression of genes involved in cell adhesion rose in the
stage that was RAD, but dropped again in the stage that
was CR.
Altogether, genes with functional categories that were
enriched in expression trends may be consistent with the
AR signaling pathway playing a role in progression of
Table 1 Composition of LongSAGE libraries
Library S1885 S1886 S1887 S1888 S1889 S1890 S1891 S1892 S1893
Mouse-Condition 13N-AS* 13N-RAD† 13N-CR‡ 15N-AS 15N-RAD 15N-CR 13R-AS 13R-RAD 13R-CR
Unfiltered Total Tags 310,516 318,102 339,864 338,210 310,072 326,870 337,546 314,440 335,504
No. of Bad Tags 955 1,010 1,083 1,097 983 737 900 744 832
Minus Bad Tags
Total Tags 309,561 317,092 338,781 337,113 309,089 326,133 336,646 313,696 334,672
Tag Types 79,201 96,973 99,730 81,850 84,499 88,249 79,859 91,438 90,675
No. of Duplicate Ditags 19,761 12,220 12,678 21,973 17,471 12,836 24,552 12,786 13,127
% of Duplicate Ditags 6.38 3.85 3.74 6.52 5.65 3.94 7.29 4.08 3.92
Average QF§ of Tags 0.85 0.88 0.87 0.86 0.89 0.88 0.88 0.80 0.87
No. of Tags QF < 0.95 63,057 62,872 71,576 68,993 54,627 54,470 68,981 101,215 69,647
Q ≥ 0.95
Total Tags 246,504 254,220 267,205 268,120 254,462 271,663 267,665 212,481 265,025
Tag Types 52,033 67,542 66,748 52,606 59,374 64,985 53,715 54,682 64,837
Total Tags Combined 2,307,345
Tag Types Combined 263,199
No. of LDTs II Type I 124 72 174 179 84 186 164 118 301
No. of LDTs Type II 19 9 54 56 33 40 60 24 59
Minus LDTs
Total Tags 246,361 254,139 266,977 267,885 254,345 271,437 267,441 212,339 264,665
Tag Types 52,031 67,540 66,746 52,604 59,372 64,983 53,713 54,680 64,835
Total Tags Combined 2,305,589
Tag Types Combined 263,197
* AS, Androgen-sensitive/
† RAD, Responsive to androgen-deprivation.
‡ CR, Castration-recurrent.
§ QF, Quality Factor.
II LDTs, Linker-derived tags.
0.1
S1892 / 13R-RAD
S1893 / 13R-CR
S1887 / 13N-CR
S1890 / 15N-CR
S1889 / 15N-RAD
S1886 / 13N-RAD
S1891 / 13R-AS
S1885 / 13N-AS
S1888 / 15N-AS
Figure 1 Clustering of the nine LongSAGE libraries in a hierarchical tree. The tree was generated using a Pearson correlation-based hierarchical
clustering method and visualized with TreeView. LongSAGE libraries constructed from similar stages of prostate cancer progression (AS, androgen-
sensitive; RAD, responsive to androgen-deprivation; and CR, castration-recurrent) cluster together. 13N, 15N, and 13R indicate the identity of each
animal.
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example, GO terms steroid binding, steroid hormone
receptor activity, heat shock protein activity, chaperone
activity, and kinase activity could represent the cytoplas-
mic events of AR signaling. GO terms transcription
factor activity, regulation of transcription, transcription
corepression activity, and transcription co-activator activ-
ity could represent the nuclear events of AR signaling.
AR-mediated gene transcription may result in splicing
and protein translation, to regulate general cellular
processes such as proliferation (and related nucleotide
synthesis, DNA replication, oxidative phosphorylation,
oxioreductase activity, and glycolysis), secretion, and
differentiation.
It should be noted, however, that both positive and
negative regulators were represented in the GO enriched
categories (Figure 3). Therefore, a more detailed analysis
was required to determine if the pathways represented
by the GO-enriched categories were promoted or inhib-
ited during progression to CRPC. Moreover, many of
the GO enrichments that were consistent with changes
in the AR signaling pathway were generic, and could be
applied to the other models of CRPC.
Consistent differential gene expression associated with
progression of prostate cancer
Pair-wise comparisons were made between LongSAGE
libraries representing the transcriptomes of different stages
(AS, RAD, and CR) of prostate cancer progression from
the same biological replicate (3 mice: 13N, 15N, or 13R).
Among all three biological replicates, the number of con-
sistent statistically significant differentially expressed tag
types were determined using the Audic and Claverie test
statistic [36] at p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001 (Table 2).
The tags represented in Table 2 were included only if the
associated expression trend was common among all three
biological replicates. The Audic and Claverie statistical
method is well-suited for LongSAGE data, because the
method takes into account the sizes of the libraries and
tag counts. Tag types were counted multiple times if they
were over, or under-represented in more than one com-
parison. The number of tag types differentially expressed
decreased by 57% as the stringency of the p-value
increased from p ≤ 0.05 to 0.001.
Tag types consistently differentially expressed in pair-
wise comparisons were mapped to RefSeq (March 4th,
2008). Tags that mapped anti-sense to genes, or mapped
ambiguously to more than one gene were not included in
the functional analysis. GO, Kyoto Encyclopedia of Genes
and Genomes (KEGG; v45.0) [37] pathway, and SwissProt
(v13.0) [38] keyword annotation enrichment analyses
were conducted using EASE (v1.21; March 11
th, 2008)
and FatiGO (v3; March 11
th, 2008) [39] (Table 3). This
functional analysis revealed that the expression of genes
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Figure 2 K-means clustering of tag types with similar
expression trends. PoissonC with K = 10 (where K = number of
clusters) was conducted over 100 iterations separately for each
biological replicate (mice 13N, 15N, and 13R) and the results from
the iterations were combined into consensus clusters shown here.
Plotted on the x-axes are the long serial analysis of gene expression
(LongSAGE) libraries representing different stages of prostate
progression: AS, androgen-sensitive; RAD, responsive to androgen-
deprivation; and CR, castration-recurrent. Plotted on the y-axes are
the relative expression levels of each tag type, represented as a
percentage of the total tag count (for a particular tag type) in all
three LongSAGE libraries. Different colors represent different tag
types. Each of the ten clusters for each biological replicate are
labeled as such. ‘No equivalent’ indicates that a similar expression
trend was not observed in the indicated biological replicate. Eleven
expression patterns are evident in total and are labeled on the left.
K-means clusters were amalgamated into five major expression
trends: group 1, up during progression; group 2, down during
progression; group 3, peak in the RAD stage; group 4, constant
during progression; and group 5, valley in RAD stage.
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Page 5 of 19involved in signaling increased during progression, but
the expression of genes involved in protein synthesis
decreased during progression. Cell communication
increased in the stage that was RAD but leveled off in the
stage that was CR. Carbohydrate, lipid and amino acid
synthesis was steady in the RAD stage but increased in
the CR stage. Lastly, glycolysis decreased in the RAD
stage, but was re-expressed in the CR stage (Table 3).
Tag types differentially expressed between the RAD and
CR stages of prostate cancer were of particular interest
(Table 4). This is because these tags potentially represent
markers for CRPC and/or are involved in the mechanisms
of progression to CRPC. These 193 tag types (Table 2)
were mapped to databases RefSeq (July 9
th,2 0 0 7 ) ,M a m -
malian Gene Collection (MGC; July 9
th, 2007) [40], or
Ensembl Transcript or genome (v45.36d) [41]. Only 135 of
the 193 tag types were relevant (Table 4) with 48 tag types
that mapped ambiguously to more than one location in
the Homo Sapiens transcriptome/genome, and another 10
tag types that mapped to Mus musculus transcriptome/
genome. Mus musculus mappings may be an indication of
minor contamination of the in vivo LNCaP Hollow Fiber
model samples with host (mouse) RNA. These 135 tag
types represented 114 candidate genes with 7 tag types
that did not map to the genome, 5 tag types that mapped
to unannotated genomic locations, and 9 genes that were
associated with more than one tag type. Table 4 shows the
LongSAGE tag sequences and tag counts per million tags
in all nine libraries. Tags were sorted into groups based on
expression trends. These trends are visually represented in
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Figure 3 Gene Ontology enrichments of the five major expression trends. Plotted on the x-axis are Gene Ontology (GO) categories
enriched in one or more of the five major expression trends. On the z-axis the five major expression trends correspond to Figure 2 and are:
group 1, up during progression; group 2, down during progression; group 3, peak in the RAD stage; group 4, constant during progression; and
group 5, valley in RAD stage. The y-axis displays the number of biological replicates (number of mice: 1, 2, or 3) exhibiting enrichment. The latter
allows one to gauge the magnitude of the GO enrichment and confidence.
Table 2 Number of tag types consistently and
significantly differentially expressed among all three
biological replicates and between conditions*
Comparison Change p ≤ 0.001 p ≤ 0.01 p ≤ 0.05
AS† vs. RAD‡ Up in RAD 21 44 83
Down in RAD 68 105 149
Total 89 149 232
RAD vs. CR§ Up in CR 24 45 89
Down in CR 46 59 104
Total 70 104 193
AS vs. CR Up in CR 111 167 294
Down in CR 127 168 256
Total 238 335 550
* Statistics according to the Audic and Claverie test statistic.
† AS, Androgen-sensitive.
‡ RAD, Responsive to androgen-deprivation.
§ CR, Castration-recurrent.
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Page 6 of 19Table 3 Top five enrichments of functional categories of tags consistently and significantly differentially expressed
among all three biological replicates and between stages of prostate cancer*
Top 5 GO † categories P-value
‡
Top 5 KEGG § annotations P-value
II
Top 5 SwissProt annotations P-value
II
AS vs. RAD: Up in RAD¶
Cell communication 2.E-02 Stilbene, coumarine and lignin biosynthesis 1.E-02 Antioxidant 7.E-04
Extracellular 2.E-02 Butanoate metabolism 2.E-02 Cell adhesion 5.E-03
Extracellular matrix 2.E-02 2,4-Dichlorobenzoate degradation 2.E-02 Signal 6.E-03
Synaptic vesicle transport 3.E-02 Cell adhesion molecules (CAMs) 2.E-02 Fertilization 7.E-03
Synapse 4.E-02 Alkaloid biosynthesis II 5.E-02 Amyotrophic lateral sclerosis 7.E-03
AS vs. RAD: Down in RAD
Glycolysis 3.E-05 Glycolysis/Gluconeogenesis 3.E-05 Glycolysis 3.E-07
Glucose catabolism 1.E-04 Ribosome 2.E-03 Pyrrolidone carboxylic acid 8.E-05
Hexose catabolism 1.E-04 Carbon fixation 3.E-03 Pyridoxal phosphate 2.E-04
Hexose metabolism 2.E-04 Fructose and mannose metabolism 2.E-02 Gluconeogenesis 3.E-04
Monosaccharide catabolism 2.E-04 Urea cycle and metabolism of amino groups 3.E-02 Coiled coil 5.E-03
RAD vs. CR: Up in CR
Acid phosphatase activity 4.E-02 gamma-Hexachlorocyclohexane degradation 5.E-03 Lyase 2.E-03
Lyase activity** 7.E-02 Glycolysis/Gluconeogenesis 3.E-02 Immune response 5.E-03
Carbohydrate metabolism** 9.E-02 O-Glycan biosynthesis 5.E-02 Signal 6.E-03
Extracellular** 1.E-01 Ether lipid metabolism** 6.E-02 Glycolysis 7.E-03
Catabolism** 1.E-01 Phenylalanine, tyrosine and tryptophan
biosynthesis**
6.E-02 Progressive external
ophthalmoplegia
1.E-02
RAD vs. CR: Down in CR
Cytosolic ribosome 2.E-09 Ribosome 2.E-11 Ribosomal protein 6.E-10
Large ribosomal subunit 1.E-07 Urea cycle and metabolism of amino groups 1.E-02 Ribonucleoprotein 3.E-08
Cytosol 2.E-07 Arginine and proline metabolism 4.E-02 Acetylation 1.E-05
Cytosolic large ribosomal
subunit
2.E-07 Type II diabetes mellitus** 1.E-01 Elongation factor 1.E-03
Protein biosynthesis 2.E-07 Phenylalanine metabolism** 1.E-01 rRNA-binding 2.E-03
AS vs. CR: Up in CR
Synapse 4.E-03 Butanoate metabolism 2.E-03 Glycoprotein 2.E-03
Extracellular 5.E-03 Ascorbate and aldarate metabolism 2.E-02 Vitamin C 7.E-03
Transition metal ion binding 7.E-03 Phenylalanine metabolism 2.E-02 Lipoprotein 1.E-02
Metal ion binding 2.E-02 Linoleic acid metabolism 2.E-02 Signal 1.E-02
Extracellular matrix 2.E-02 gamma-Hexachlorocyclohexane degradation 2.E-02 Heparin-binding 1.E-02
AS vs. CR: Down in CR
Cytosolic ribosome 4.E-12 Ribosome 2.E-09 Acetylation 2.E-07
Biosynthesis 7.E-11 Carbon fixation 9.E-04 Ribosomal protein 1.E-06
Macromolecule biosynthesis 2.E-10 Glycolysis/Gluconeogenesis 3.E-03 Glycolysis 7.E-05
Protein biosynthesis 1.E-08 Glycosphingolipid biosynthesis - lactoseries 4.E-02 Ribonucleoprotein 8.E-05
Eukaryotic 43 S preinitiation
complex
2.E-08 Glutamate metabolism** 8.E-02 Protein biosynthesis 1.E-04
* Statistics according to the Audic and Claverie test statistic (p ≤ 0.05).
† GO, Gene Ontology.
‡ P-value represents the raw EASE (Expression Analysis Systematic Explorer) score.
§ KEGG, Kyoto Encyclopedia of Genes and Genomes.
II Unadjusted p-value was computed using FatiGO.
¶ AS, androgen-sensitive; RAD, responsive to androgen-deprivation; CR, castration-recurrent.
** Not statistically significant (p > 0.05).
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Page 7 of 19Table 4 Gene expression trends of LongSAGE tags that consistently and significantly altered expression in CR prostate
cancer*
13N 15N 13R
AS§ RADII CR¶ AS RAD CR AS RAD CR
Tag Sequence S1885 S1886 S1887 S1888 S1889 S1890 S1891 S1892 S1893 Trend‡ Gene** Accession§§
TCTAGAGAACACTGTGC 12† 79 382 7 67 136 7 52 200 A ACPP‡‡ NM_001099
TAATTTTTCTAAGGTGT 101 311 648 119 397 895 120 546 918 A C1ORF80 ENSG00000186063
TGAGAGAGGCCAGAACA 8 39 150 4 39 144 7 33 95 A N/A Genomic
CTCATAAGGAAAGGTTA 637 952 1680 653 1170 1540 688 1620 1930 A RNF208 BC090061
GATTTCTATTTGTTTTT 89 169 446 116 208 339 86 311 555 A SERINC5 ENSG00000164300
GTTGGGAAGACGTCACC 426 571 742 273 417 741 262 363 495 A STEAP1 NM_012449
GAGGATCACTTGAGGCC 191 299 449 134 189 589 187 203 314 B AMACR‡‡ BC009471
TTGTTGATTGAAAATTT 219 197 528 273 197 479 232 391 586 B AMD1‡‡ NM_001634
TTTGCTTTTGTTTTGTT 53 16 169 34 51 129 7 28 72 B AQP3 NM_004925
GTTCGACTGCCCACCAG 45 28 101 52 47 122 34 42 106 B ASAH1†† NM_177924
TAATAAACAGGTTTTTA 426 232 648 332 315 700 138 250 491 B ASAH1‡‡ NM_177924
TCACAGCTGTGAAGATC 85 110 277 161 71 258 310 438 945 B BTG1 NM_001731
AAAAGAGAAAGCACTTT 24 75 199 19 35 85 15 90 552 B CAMK2N1 NM_018584
CAAAACAGGCAGCTGGT 4 71 169 15 83 162 37 75 268 B CAMK2N1†† NM_018584
AGGAGGAAGAATGGACT 33 59 187 49 67 247 26 42 223 B CCNH NM_001239
TTTTAAAAATATAAAAT 89 83 243 97 130 269 64 170 382 B COMT NM_000754
GAATGAAATAAAAAATA 134 252 626 209 240 357 116 160 272 B DHRS7 NM_016029
AAAGTGCATCCTTTCCC 118 146 318 153 220 394 288 231 646 B FGFRL1 NM_001004356
AAACTGAATAAGGAGAA 24 51 236 19 51 438 19 146 283 B GALNT3 NM_004482
TTTAAGGAAACATTTGA 4 4 75 4 4 81 0 0 57 B GALNT3†† NM_004482
CCAACCGTGCTTGTACT 191 327 521 202 279 534 172 363 510 B GLO1 NM_006708
GAGGGCCGGTGACATCT 300 378 1170 321 476 1230 254 447 1030 B H2AFJ NM_177925
TATCATTATTTTTACAA 57 63 161 67 63 181 75 94 181 B HSD17B4 NM_000414
AATGCACTTATGTTTGC 16 8 64 22 16 77 19 28 98 B N/A No map
ACCTTCGCAGGGGAGAG 0 0 19 0 4 41 0 5 34 B N/A Genomic
ATAACCTGAAAGGAAAG 0 16 56 7 4 74 0 28 87 B N/A No map
GTGATGTGCACCTGTTG 0 0 38 4 0 30 0 5 45 B N/A No map
GTTTGGAGGTACTAAAG 20 43 94 34 87 169 34 90 234 B N/A Genomic
TTTTCAAAAATTGGAAA 0 35 180 7 4 59 0 19 61 B N/A No map
GAAAAATTTAAAGCTAA 394 397 569 433 598 788 853 862 1060 B NGFRAP1 NM_206917
CAAATTCAGGGAGCACA 0 4 139 4 16 228 0 14 136 B OPRK1 NM_000912
CTATTGTCTGAACTTGA 0 8 109 0 12 70 0 9 227 B OR51E2 BC020768
ATGCTAATTATGGCAAT 4 12 75 4 8 74 0 5 57 B PCGEM1 NR_002769
CAGAAAGCATCCCTCAC 4 43 195 0 16 111 7 33 264 B PLA2G2A‡‡ NM_000300
TAATTTTAGTGCTTTGA 16 75 154 37 59 162 4 57 132 B PTGFR NM_000959
TTGTTTGTAAATAGAAT 0 12 94 0 4 162 0 14 72 B QKI NM_206853
TAAACACTGTAAAATCC 0 4 75 0 4 66 0 0 42 B QKI†† NM_206853
AGCAGATCAGGACACTT 20 35 112 15 16 140 15 42 98 B S100A10 NM_002966
CTGCCATAACTTAGATT 37 55 161 93 63 192 56 99 264 B SBDS NM_016038
TGGCTGAGTTTATTTTT 20 24 79 41 8 96 4 42 147 B SFRS2B NM_032102
GAAGATTAATGAGGGAA 126 142 277 108 130 402 101 188 325 B SNX3 NM_003795
ATGGTACTAAATGTTTT 16 47 124 37 28 88 11 19 76 B SPIRE1 NM_020148
TATATATTAAGTAGCCG 45 39 101 45 75 133 41 75 178 B STEAP2‡‡ NM_152999
CAACAATATATGCTTTA 24 32 82 75 32 136 26 99 212 B STEAP2†† NM_152999
TTTCATTGCCTGAATAA 24 43 150 34 59 114 22 61 178 B TACC1‡‡ NM_006283
TTGGCCAGTCTGCTTTC 8 16 67 4 4 77 0 5 38 B TMEM30A ENSG00000112697
ATATCACTTCTTCTAGA 12 4 26 7 4 26 0 52 140 C ADAM2‡‡ NM_001464
ATGTGTGTTGTATTTTA 812 338 768 1010 315 1020 269 702 865 C BNIP3 NM_004052
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Page 8 of 19Table 4: Gene expression trends of LongSAGE tags that consistently and significantly altered expression in CR pros-
tate cancer* (Continued)
CCACGTTCCACAGTTGC 601 291 599 530 346 700 381 339 559 C ENO2 NM_001975
CTGATCTGTGTTTCCTC 16 0 26 0 4 41 19 0 34 C HLA-B BC013187
AGCCCTACAAACAACTA 382 441 596 508 456 619 400 631 1010 C MT-ND3 ENSG00000198840
ATATTTTCTTTGTGGAA 20 12 90 7 0 48 4 0 23 C N/A No map
CAAGCATCCCCGTTCCA 2400 2130 2440 2730 1720 2250 1020 2010 2340 C N/A ENSG00000211459
GTTGTAAAATAAACTTT 118 83 172 228 87 247 112 203 378 C N/A Genoic
TTGGATTTCCAAAGCAG 12 0 19 0 0 33 0 0 26 C N/A Genomic
TCTTTTAGCCAATTCAG 138 181 420 381 326 468 389 334 457 C NKX3-1†† NM_006167
TGATTGCCCTTTCATAT 73 39 86 86 39 107 108 99 181 C P4HA1 NM_000917
GTAACAAGCTCTGGTAT 28 16 56 49 24 66 11 19 72 C PJA2 NM_014819
ACAGTGCTTGCATCCTA 85 75 139 108 98 203 101 118 196 C PPP2CB NM_004156
AGGCGAGATCAATCCCT 57 39 101 37 24 122 131 66 268 C PSMA7 NM_002792
TATTTTGTATTTATTTT 73 59 180 93 51 111 22 94 253 C SLC25A4 NM_001151
TTATGGATCTCTCTGCG 1050 1260 1820 1140 1300 2260 1990 1010 1530 C SPON2 NM_012445
CAGTTCTCTGTGAAATC 767 515 1060 855 503 914 467 608 1200 C TMEM66 NM_016127
AAATAAATAATGGAGGA 138 59 255 82 118 284 165 90 159 C TRPM8 NM_024080
ATGTTTAATTTTGCACA 61 87 154 157 59 195 217 85 344 C WDR45L NM_019613
GGGCCCCAAAGCACTGC 861 543 1180 1020 657 1590 1240 739 937 E C19orf48 NM_199249
TCCCCGTGGCTGTGGGG 1670 1390 2290 1740 1410 1720 3370 970 1180 E DHCR24‡‡ BC004375
GCATCTGTTTACATTTA 487 201 345 444 208 468 684 226 423 E ELOVL5 NM_021814
GAAATTAGGGAAGCCTT 317 153 311 310 181 542 359 193 298 E ENDOD1 XM_290546
GGATGGGGATGAAGTAA 2780 1160 4780 2950 1350 3620 2930 1230 1890 E KLK3‡‡ NM_001648
TGAAAAGCTTAATAAAT 313 142 322 474 181 332 273 179 314 E TPD52 NM_001025252
GTTGTGGTTAATCTGGT 1770 634 1270 1800 806 1190 2480 659 960 F B2M NM_004048
GAAACAAGATGAAATTC 4380 1170 2260 5300 1110 2720 3750 2220 2830 F PGK1 NM_000291
AGCACCTCCAGCTGTAC 2150 1130 648 2060 1560 939 1560 1200 722 G EEF2 NM_001961
GCACAAGAAGATTAAAA 536 228 124 762 425 195 838 278 174 G GAS5 NR_002578
CCGCTGCGTGAGGGCAG 451 169 56 429 197 44 516 94 0 G HES6 NM_018645
GCCCAGGTCACCCACCC 585 55 4 519 79 7 456 66 0 G LOC644844 XM_927939
ATGCAGCCATATGGAAG 2650 386 82 2470 216 129 1210 259 98 G ODC1 NM_002539
CGCTGGTTCCAGCAGAA 1420 811 479 1250 959 553 800 589 374 G RPL11 NM_000975
AAGACAGTGGCTGGCGG 2650 1730 1220 2460 1860 1350 2120 1630 1270 G RPL37A‡‡ NM_000998
TTCTTGTGGCGCTTCTC 925 543 217 1030 708 273 1130 419 306 G RPS11†† NM_001015
GGTGAGACACTCCAGTA 463 252 165 485 346 192 363 245 159 G SLC25A6 NM_001636
AGGTTTTGCCTCATTCC 982 515 281 1200 491 243 688 782 166 H ABHD2 NM_007011
TGAAGGAGCCGTCTCCA 317 272 187 392 295 199 366 259 140 H ATP5G2 NM_001002031
CTCAGCAGATCCAAGAG 191 185 67 254 232 66 142 231 79 H C17orf45 NM_152350
CTGTGACACAGCTTGCC 308 397 172 209 307 125 295 226 110 H CCT2 NM_006431
TCTGCACCTCCGCTTGC 495 606 277 426 570 276 366 471 204 H EEF1A2 NM_001958
GCCCAAGGACCCCCTGC 114 114 38 138 98 41 101 42 4 H FLNA‡‡ NM_001456
TTATGGGATCTCAACGA 564 425 180 642 452 317 430 490 253 H GNB2L1 NM_006098
TCTGCAAAGGAGAAGTC 81 102 38 105 87 26 165 80 30 H HMGB2 NM_002129
CTTGTGAACTGCACAAC 268 228 124 231 177 103 273 160 57 H HN1 NM_016185
TCTGAAGTTTGCCCCAG 313 291 150 254 299 155 187 226 72 H MAOA NM_000240
TTAATTGATAGAATAAA 483 350 199 422 287 103 273 235 83 H MAOA NM_000240
GGCAGCCAGAGCTCCAA 1200 1260 420 1050 672 350 681 819 23 H MARCKSL1 NM_023009
CCCTGCCTTGTCCCTCT 353 240 112 310 263 107 176 193 102 H MDK NM_001012334
CTGTGGATGTGTCCCCC 649 476 169 459 389 214 430 297 117 H N/A No map
CTCCTCACCTGTATTTT 1120 771 262 1220 979 313 666 730 261 H RPL13A‡‡ NM_012423
GCAGCCATCCGCAGGGC 1980 1770 809 2300 1730 928 2150 1570 1020 H RPL28 NM_000991
GGATTTGGCCTTTTTGA 3470 2070 1370 4170 2910 1540 2800 2870 2500 H RPLP2‡‡ NM_001004
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Page 9 of 19Additional file 1, Figure S3. Mapping information was pro-
vided where available.
We cross-referenced these 114 candidate genes with 28
papers that report global gene expression analyses on
tissue samples from men with ‘castration-recurrent’,
‘androgen independent,’‘ hormone refractory,’‘ androgen-
ablation resistant,’‘ relapsed,’ or ‘recurrent’ prostate can-
cer, or animal models of castration-recurrence [42-69].
Table 4: Gene expression trends of LongSAGE tags that consistently and significantly altered expression in CR pros-
tate cancer* (Continued)
TCTGTACACCTGTCCCC 2320 1670 850 1930 1880 825 2130 1490 1120 H RPS11 NM_001015
GCTTTTAAGGATACCGG 1510 1050 626 1860 1120 593 1550 1550 960 H RPS20‡‡ NM_001023
CCCCAGCCAGTCCCCAC 921 519 281 788 664 357 1100 438 291 H RPS3 NM_001005
CCCCCAATGCTGAGGCC 89 138 26 90 94 30 90 80 30 H SF3A2 NM_007165
GCCGCCATCTCCGAGAG 195 102 30 168 118 55 172 108 30 H TKT NM_001064
GGCCATCTCTTCCTCAG 349 307 202 317 346 173 277 254 121 H YWHAQ NM_006826
AGGCTGTGTTCCTCCGT 16 39 11 34 67 22 26 38 8 I ACY1 NM_000666
TGCCTCTGCGGGGCAGG 446 649 427 399 664 424 501 462 317 I CD151 NM_004357
GGCACAGTAAAGGTGGC 175 216 142 332 350 173 456 316 204 I CUEDC2 NM_024040
TCACACAGTGCCTGTCG 49 71 7 30 47 15 34 66 4 I CXCR7 NM_001047841
TGTGAGGGAAGCTGCTT 53 87 15 67 102 52 52 90 42 I FKBP10 BC016467
TGCTTTGCTTCATTCTG 28 63 26 22 79 26 49 118 61 I GRB10 NM_005311
GTACTGTATGCTTGCCA 170 212 82 134 153 88 123 188 113 I KPNB1‡‡ NM_002265
GTGGCAGTGGCCAGTTG 106 193 97 123 173 96 94 137 76 I N/A ENSG00000138744
GGGGAGCCCCGGGCCCG 61 63 26 30 51 18 34 57 0 I NAT14 NM_020378
TGTTCAGGACCCTCCCT 28 67 26 60 63 26 60 28 0 I NELF NM_015537
TTTTCCTGGGGATCCTC 41 130 15 37 87 33 56 104 45 I PCOTH NM_001014442
GAAACCCGGTAGTCTAG 41 75 4 37 75 26 52 151 30 I PLCB4 NM_000933
GTCTGACCCCAGGCCCC 126 205 82 119 193 103 157 179 38 I PPP2R1A NM_014225
GGCCCGAGTTACTTTTC 231 150 75 161 232 136 142 160 45 I RPL35A†† NM_000996
GTTCGTGCCAAATTCCG 881 696 390 1100 712 523 497 782 461 I RPL35A‡‡ NM_000996
TTACCATATCAAGCTGA 877 535 311 1130 598 405 636 791 578 I RPL39‡‡ NM_001000
GCTGCAGCACAAGCGGC 268 244 127 45 216 125 157 71 11 I RPS18†† NM_022551
AGCTCTTGGAGGCACCA 203 319 206 142 421 243 269 259 162 I SELENBP1 NM_003944
TGCTGGTGTGTAAGGGG 69 102 45 82 87 37 105 75 30 I SH3BP5L NM_030645
GAGAGTAACAGGCCTGC 191 150 71 112 181 111 108 165 64 I SYNC1 NM_030786
CTGAAAACCACTCAAAC 394 508 225 306 547 236 310 381 200 I TFPI NM_006287
TAAAAAAGGTTTCATCC 183 248 127 86 130 66 142 268 87 I TFPI NM_006287
CTCCCTCCTCTCCTACC 28 32 4 30 39 7 71 24 0 I TK1 NM_003258
CATTTTCTAATTTTGTG 544 744 236 407 771 181 288 664 185 J N/A No map
TGATTTCACTTCCACTC 3480 5260 3910 3700 6110 3590 3040 5960 2600 K MT-CO3 ENSG00000198938
TTTCTGTCTGGGGAAGG 130 236 82 123 201 111 101 188 113 K PIK3CD NM_005026
GCCGCTACTTCAGGAGC 256 370 199 224 330 169 142 316 38 K RAMP1 NM_005855
ATGGTTACACTTTTGGT 93 161 94 75 208 118 60 226 95 K UTX NM_021140
CACTACTCACCAGACGC 2820 3900 3020 2740 4290 2440 2620 3120 1260 K VPS13B†† ENSG00000132549
CTAAGACTTCACCAGTC 7120 11000 9730 6390 10900 8330 3610 8870 7850 L N/A ENSG00000210082
* Statistics according to the Audic and Claverie test statistic (p ≤ 0.05).
† Tag count per 1 million = (observed tag count/total tags in the library) × 1,000,000.
‡ Trends are visually represented from A to P in Additional file 1, Figure S3. In addition to p-value considerations, significantly different trends were also required
to display uniform directions of change in each biological replicate.
§ AS, Androgen-sensitive.
II RAD, Responsive to androgen-deprivation.
¶ CR, Castration-recurrent.
** Human Genome Nomenclature Committee (HGNC)-approved gene names were used when possible. Non-HGNC-approved gene names were not italicized.
†† Tag maps antisense to gene.
‡‡ Gene is known to display this expression trend in castration-recurrence.
§§ Accession numbers were displayed following the priority (where available): RefSeq > Mammalian Gene Collection > Ensembl Gene. If the tag mapped to more
than one transcript variant of the same gene, the accession number of the lowest numerical transcript variant was displayed.
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Page 10 of 19The candidate genes were identified with HUGO Gene
Nomenclature Committee (HGNC) approved gene
names, aliases, descriptions, and accession numbers. The
gene expression trends of 18 genes of 114 genes were
previously associated with CRPC. These genes were:
ACPP, ADAM2, AMACR, AMD1, ASAH1, DHCR24,
FLNA, KLK3, KPNB1, PLA2G2A, RPL13A, RPL35A,
RPL37A, RPL39, RPLP2, RPS20, STEAP2,a n dTACC
(Table 4). To our knowledge, the gene expression trends
of the remaining 96 genes have never before been asso-
ciated with CRPC (Tables 4 &5).
A literature search helped to gauge the potential of
these 96 genes to be novel biomarkers or therapeutic
targets of CRPC. The results of this literature search
are presented in Table 5. We found 31 genes that
encode for protein products that are known, or pre-
dicted, to be plasma membrane bound or secreted
extracellularly (Bioinformatic Harvester). These genes
were: ABHD2, AQP3, B2 M, C19orf48, CD151, CXCR7,
DHRS7, ELOVL5, ENDOD1, ENO2, FGFRL1, GNB2L1,
GRB10, HLA-B, MARCKSL1, MDK, NAT14, NELF,
OPRK1, OR51E2, PLCB4, PTGFR, RAMP1, S100A10,
SPON2, STEAP1, TFPI, TMEM30A, TMEM66, TRPM8,
and VPS13B. Secretion of a protein could facilitate
detection of the putative biomarkers in blood, urine, or
biopsy sample. Twenty-one of the candidate genes are
known to alter their levels of expression in response to
androgen. These genes were: ABHD2, B2 M, BTG1,
C19orf48, CAMK2N1, CXCR7, EEF1A2, ELOVL5,
E N D O D 1 ,H S D 1 7 B 4 ,M A O A ,M D K ,N K X 3 - 1 ,O D C 1 ,
P4HA1, PCGEM1, PGK1, SELENBP1, TMEM66,
TPD52,a n dTRPM8 [9,22,70-81]. Genes regulated by
androgen may be helpful in determining the activation
status of AR in CRPC. Enriched expression of a pro-
tein in prostate tissue could be indicative of whether a
tumor is of prostatic origin. Eight of these 96 genes
are known to be over-represented in prostate tissue
[75,82-85]. These genes were: ELOVL5, NKX3-1,
P C G E M 1 ,P C O T H ,R A M P 1 ,S P O N 2 ,S T E A P 1 ,a n d
TPD52. Twenty-six genes (ABHD2, BNIP3, EEF1A2,
ELOVL5, GALNT3, GLO1, HSD17B4, MARCKSL1,
MDK, NGFRAP1, ODC1, OR51E2, PCGEM1,P C O T H ,
PGK1, PP2CB, PSMA7, RAMP1, RPS18, SELENBP1,
SLC25A4, SLC25A6, SPON2, STEAP1, TPD52,a n d
TRPM8) have known associations to prostate cancer
[57,82,86-102]. Six genes (C1orf80, CAMK2N1, GLO1,
MAOA, PGK1,a n dSNX3) have been linked to high
Gleason grade [58,103,104], and twelve genes (B2 M,
CAMK2N1, CD151, COMT, GALNT3, GLO1, ODC1,
PCGEM1,P C O T H ,SBDS, TMEM30A,a n dTPD52)
have been implicated in the ‘progression’ of prostate
cancer [58,82], and 15 more genes (CD151, CXCR7,
DHRS7, GNB2L1, HES6, HN1, NKX3-1, PGK1,
P I K 3 C D ,R P L 1 1 ,R P S 1 1 ,S F 3 A 2 ,T K 1 ,T P D 5 2 ,a n d
VPS13B) in the metastasis of prostate cancer [105,106].
Novel CR-associated genes identify both clinical samples
of CRPC and clinical metastasis of prostate cancer
The expression of novel CR-associated genes were vali-
dated in publically available, independent sample sets
representing different stages of prostate cancer progres-
sion (Gene Expression Omnibus accession numbers:
GDS1390 and GDS1439). Dataset GDS1390 includes
expression data of ten AS prostate tissues, and ten CRPC
tissues from Affymetrix U133A arrays [47]. Dataset
GDS1439 includes expression data of six benign prostate
tissues, seven localized prostate cancer tissues, and seven
metastatic prostate cancer tissues from Affymetrix U133
2.0 arrays [97].
Unsupervised principal component analysis based on
the largest three principal components revealed separate
clustering of tumor samples representing AS and CR
stages of cancer progression, with the exception of two
CR samples and one AS sample (Figure 4a).
Metastatic prostate cancer is expected to have a more
progressive phenotype and is associated with hormonal
progression. Therefore, the gene expression signature
obtained from the study of hormonal progression may
be common to that observed in clinical metastases.
Unsupervised principal component analysis based on the
largest three principal components revealed separate
clustering of not only benign and malignant, but also
localized and metastatic tissue samples (Figure 4b).
Discussion
Genes that change levels of expression during hormonal
p r o g r e s s i o nm a yb ei n d i c a t i v eo ft h em e c h a n i s m s
involved in CRPC. Here we provide the most compre-
hensive gene expression analysis to date of prostate can-
cer with approximately 3 million long tags sequenced
using in vivo samples of biological replicates at various
stages of hormonal progression to improve over the pre-
vious libraries that are approximately 70,000 short tags
or less. Previous large-scale gene expression analyses
have been performed with tissue samples from men
with advanced prostate cancer [42-58], and animal or
xenograft models of CRPC [59-69]. Most of these pre-
vious studies compared differential expression between
CRPC samples with the primary samples obtained
before androgen ablation. This experimental design can-
not distinguish changes in gene expression that are a
direct response to androgen ablation, or from changes
in proliferation/survival that have been obtained as the
prostate cancer cells progress to more a more advanced
phenotype. Here we are the first to apply an in vivo
model of hormonal progression to compare gene
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Page 11 of 19Table 5 Characteristics of genes with novel association to castration-recurrence in vivo
Associated with Associated with
Gene* S or
PM†
Reg.
by A‡
Spec.
to P§
CaPII GG¶ Prog.
**
Mets†† CR‡‡ Gene S or
PM
Reg.
by A
Spec.
to P
CaP GG Prog. Mets CR
ABHD2 PM Y↑ -Y ↑ -- - - NKX3-1 -Y ↑ Y- - -Y -
ACY1 -- -- - --- ODC1 -Y ↑ -Y ↑ -Y ↓ -Y ↑
AQP3 PM - - - - - - - OPRK1 PM - - - - - - -
ATP5G2 -- -- - --- OR51E2 PM - - Y↑ -- --
B2M S&PM Y↑ -- - Y ↑ -Y ↓ P4HA1 -Y -- - - - -
BNIP3 -- - Y ↓ -- - - PCGEM1 -Y ↑ YY ↑ -Y ↑ --
BTG1 -Y ↓ - - - - - - PCOTH - - Y Y↑ -Y ↑ --
C17orf45 -- -- - --- PGK1 -Y ↑ -Y ↓ Y↑ -Y
↑↓§§
-
C19orf48 S Y↑ - - - - - - PIK3CD - - - - - - Y↑ Y↑
C1orf80 - - - - Y↑ - - - PJA2 - - - - - - - -
CAMK2N1 - Y↓ -- Y ↑ Y↑ - - PLCB4 PM - - - - - - -
CCNH - - - - - - - - PPP2CB - - - Y↓ -- --
CCT2 - - - - - - - - PPP2R1A - - - - - - - -
CD151 PM - - - - Y↑ Y↑ - PSMA7 - - - Y↓ -- --
COMT - - - - - Y↓ - - PTGFR PM - - - - - - -
CUEDC2 - - - - - - - - QKI - - - - - - - -
CXCR7 PM Y↓ -- - - Y ↑ Y↑ RAMP1 PM - Y Y↑ -- --
DHRS7 PM - - - - - Y↓ - RNF208 - - - - - - - -
EEF1A2 - Y↑ -Y ↑ - - - - RPL11 - - - - - - Y↓ -
EEF2 - - - - - - - - RPL28 - - - - - - - -
ELOVL5 PM Y Y Y↓ - - - - RPS11 - - - - - - Y↓ -
ENDOD1 SY ↑ -- - --- RPS18 -- - Y ↑ -- --
ENO2 PM - - - - - - - RPS3 -- - - - - - -
ENSG00000210082 - - - - - - - - S100A10 PM - - - - - - -
ENSG00000211459 - - - - - - - - SBDS -- - - - Y ↑ --
FGFRL1 PM - - - - - - - SELENBP1 -Y ↓ -Y ↓ -- --
FKBP10 -- -- - --- SERINC5 -- - - - - - -
GALNT3 -- - Y ↑ -Y ↓ -- SF3A2 -- - - - - Y ↑ -
GAS5 - - - - - - - - SFRS2B - - - - - - - -
GLO1 - - - Y↑ Y↑ Y↑ - - SH3BP5L - - - - - - - -
GNB2L1 PM - - - - - Y↑ - SLC25A4 - - - Y↑ -- --
GRB10 PM - - - - - - - SLC25A6 - - - Y↑ -- --
H2AFJ - - - - - - - - SNX3 - - - - Y↑ -- -
HES6 - - - - - - Y↑ Y↑ SPIRE1 -- - - - - - -
HLA-B PM - - - - - - - SPON2 S- Y Y ↑ -- --
HMGB2 -- -- - -- Y ↑ STEAP1 PM - Y Y↑ -- --
HN1 -- -- - - Y ↑ - SYNC1 -- - - - - - -
HSD17B4 -Y ↑ -Y ↑ -- - - TFPI S- -- - - - -
LOC644844 - - - - - - - - TK1 -- - - - - Y ↑ -
MAOA -Y -- Y ↑ --- TKT -- - - - - - -
MARCKSL1 PM - - Y↑ -- - - TMEM30A S&PM - - - - Y↑ --
MDK S&PM Y↓ -Y ↑ -- - Y ↑ TMEM66 S&PM Y↑ -- - -- -
MT-CO3 -- -- - --- TPD52 -Y ↑ YY ↑ -Y ↑ Y↓ -
MT-ND3 -- -- - --- TRPM8 PM Y↑ -Y ↑ -- - Y ↓
NAAA -- -- - -- Y ↑ UTX -- - - - - - -
NAT14 PM - - - - - - - VPS13B PM - - - - - Y↑ -
Romanuik et al. BMC Medical Genomics 2010, 3:43
http://www.biomedcentral.com/1755-8794/3/43
Page 12 of 19expression between serial samples of prostate cancer
before (AS), and after androgen ablation therapy (RAD)
as well as when the cells become CR. This model is the
LNCaP Hollow Fiber model [21] which has genomic
similarity with clinical prostate cancer [23] and mimics
the hormonal progression observed clinically in response
to host castration as measured by levels of expression of
PSA and cell proliferation. Immediately prior to castra-
tion, when the cells are AS, PSA levels are elevated and
the LNCaP cells proliferate. A few days following castra-
tion, when the cells are RAD, PSA levels drop and the
LNCaP cells cease to proliferate, but do not apoptose in
this model. Approximately 10 weeks following castra-
tion, when the cells are CR, PSA levels rise and the
LNCaP cells proliferate in the absence of androgen. This
model overcomes some limitations in other studies
using xenografts that include host contamination
of prostate cancer cells. The hollow fibers prevent
infiltration of host cells into the fiber thereby allowing
retrieval of pure populations of prostate cells from
within the fiber. The other important benefit of the
fiber model is the ability to examine progression of cells
to CRPC at various stages within the same host mouse
over time, because the retrieval of a subset of fibers
entails only minor surgery. The power to evaluate pro-
gression using serial samples from the same mouse
minimizes biological variation to enhance the gene
expression analyses. However, limitations of this model
include the lack of cell-cell contact with stroma cells,
and lack of heterogeneity in tumors. Typically, these fea-
tures would allow paracrine interactions as expected in
clinical situations. Consistent with the reported clinical
relevance of this model [23], here principal component
analysis based on the expression of these novel genes
identified by LongSAGE, clustered the clinical samples
of CRPC separately from the androgen-dependent
Table 5: Characteristics of genes with novel association to castration-recurrence in vivo (Continued)
NELF PM - - - - - - - WDR45L -- - - - - - -
NGFRAP1 -- - Y ↓ -- - - YWHAQ -- - - - - - -
* Human Genome Nomenclature Committee (HGNC)-approved gene names were used when possible. Non-HGNC-approved gene names were not italicized.
† S or PM, gene product is thought to be secreted (S) or localize to the plasma membrane (PM).
‡ Reg. by A, gene expression changes in response to androgen in prostate cells.
§ Spec. to P, gene expression is specific to- or enriched in- prostate tissue compared to other tissues.
II CaP, gene is differentially expressed in prostate cancer compared to normal, benign prostatic hyperplasia, or prostatic intraepithelial neoplasia.
¶ GG, gene is differentially expressed in higher Gleason grade tissue versus lower Gleason grade tissue.
** Prog., gene expression correlates with late-stage prostate cancer or is a risk factor that predicts progression.
†† Mets, gene expression is associated with prostate cancer metastasis in human samples or in vivo models.
‡‡ CR, gene is associated with castration-recurrent prostate cancer in human tissue or in vivo models, but exhibits an opposite trend of this report
§§ Y, yes; ↑, high gene expression; ↓, low gene expression.
Y: PCA component 2 (11.66% variance)
1
0
0
0 1
1 Z: PCA component 3 (10.45% variance)
X: PCA component 1 
(17.9% variance)
Y: PCA component 2 (20.81% variance)
X: PCA component 1
(39.13% variance)
Z: PCA component 3
(9.951% variance)
Benign
LocCaP
MetCap
AS
CR
A B
Figure 4 Principle component analyses of clinical samples. A, Principle component analysis based on the expression of novel CR-associated
genes in the downloaded dataset GDS1390 clustered the AS and CR clinical samples into two groups. B, Principle component analysis based on
the expression of novel CR-associated genes in the downloaded dataset GDS1439 clustered the clinical samples (benign prostate tissue, benign;
localized prostate cancer, Loc CaP; and metastatic prostate cancer, Met CaP) into three groups.
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expression of these genes also revealed separate cluster-
ing of the different stages of tumor samples and also
showed separate clustering of the benign samples from
the prostate cancer samples. Therefore, some common
changes in gene expression profile may lead to the sur-
vival and proliferation of prostate cancer and contribute
to both distant metastasis and hormonal progression.
We used this LNCaP atlas to identify changes in
gene expression that may provide clues of underlying
mechanisms resulting in CRPC. Suggested models of
CRPC involve: the AR; steroid synthesis and metabo-
lism; neuroendocrine prostate cancer cells; and/or an
imbalance of cell growth and cell death.
Androgen receptor (AR)
Transcriptional activity of AR
The AR is suspected to continue to play an important
role in the hormonal progression of prostate cancer.
The AR is a ligand-activated transcription factor with its
activity altered by changes in its level of expression or
by interactions with other proteins. Here, we identified
changes in expression of some known or suspected
modifier of transcriptional activity of the ARin CRPC
versus RAD such as Cyclin H (CCNH) [107], protea-
some macropain subunit alpha type 7 (PSMA7) [108],
CUE-domain-containing-2 (CUEDC2) [109], filamin A
(FLNA) [110], and high mobility group box 2 (HMGB2)
[111]. CCNH and PSMA7 displayed increased levels of
expression, while CUEDC2, FLNA,a n dHMGB2 dis-
played decreased levels of expression in CR. The expres-
sion trends of CCNH, CUEDC2, FLNA,a n dPSMA7 in
CRPC may result in increased AR signaling through
mechanisms involving protein-protein interactions or
altering levels of expression of AR. CCNH protein is a
component of the cyclin-dependent activating kinase
(CAK). CAK interacts with the AR and increases its
transcriptional activity [107]. Over-expression of the
proteosome subunit PSMA7 promotes AR transactiva-
tion of a PSA-luciferase reporter [108]. A fragment of
the protein product of FLNA negatively regulates tran-
scription by AR through a physical interaction with the
hinge region [110]. CUEDC2 protein promotes the
degradation of progesterone and estrogen receptors
[109]. These steroid receptors are highly related to the
AR, indicating a possible role for CUEDC2 in AR degra-
dation. Thus decreased expression of FLNA or CUEDC2
could result in increased activity of the AR. Decreased
expression of HMGB2 in CRPC is predicted to decrease
expression of at least a subset of androgen-regulated
genes that contain palindromic AREs [111]. Here, genes
known to be regulated by androgen were enriched in
expression trend categories with a peak or valley at the
RAD stage of prostate cancer progression. Specifically, 8
of the 13 tags (62%) exhibiting these expression trends
‘E’, ‘F’, ‘J’, ‘K’,o r‘L’ represented known androgen-
regulated genes, in contrast to only 22 of the remaining
122 tags (18%; Tables 4 &5). Overall, this data supports
increased AR activity in CRPC, which is consistent with
re-expression of androgen-regulated genes as previously
reported [68] and similarity of expression of androgen
regulated genes between CRPC and prostate cancer
before androgen ablation [23].
Steroid synthesis and metabolism
In addition to changes in expression of AR or interact-
ing proteins altering the transcriptional activity of the
AR, recent suggestion of sufficient levels of residual
androgen in CRPC provides support for an active
ligand-bound receptor [112]. The AR may become re-
activated in CRPC due to the presence of androgen that
may be synthesized by the prostate de novo [4] or
through the conversion of adrenal androgens. Here, the
expression of 5 genes known to function in steroid
synthesis or metabolism were significantly differentially
expressed in CRPC versus RAD. They are 24-dehydro-
cholesterol reductase (DHCR24) [113], dehydrogenase/
reductase SDR-family member 7 (DHRS7) [114], elonga-
tion of long chain fatty acids family member 5
(ELOVL5) [115,116], hydroxysteroid (17-beta) dehydro-
genase 4 (HSD17B4) [117], and opioid receptor kappa 1
(OPRK1) [118]. Increased levels of expression of these
genes may be indicative of the influence of adrenal
androgens, or the local synthesis of androgen, to reacti-
vate the AR to promote the progression of prostate can-
cer in the absence of testicular androgens.
Neuroendocrine
Androgen-deprivation induces neuroendocrine differen-
tiation of prostate cancer. Here, the expression of 8
genes that are associated with neuroendocrine cells were
significantly differentially expressed in CRPC versus
RAD. They either responded to androgen ablation such
as hairy and enhancer of split 6 (HES6) [119], karyo-
pherin/importin beta 1 (KPNB1) [120], monoamine oxi-
dase A (MAOA) [121], and receptor (calcitonin) activity
modifying protein 1 (RAMP1) [122]], or were increased
expressed in CRPC such as ENO2 [122], OPRK1 [118],
S100 calcium binding protein A10 (S100A10) [123], and
transient receptor potential cation channel subfamily M
member 8 (TRPM8) [124].
Proliferation and Cell survival
T h eg e n ee x p r e s s i o nt r e n d so fGAS5 [125], GNB2L1
[126], MT-ND3, NKX3-1 [127], PCGEM1 [128],
PTGFR [129], STEAP1 [130], and TMEM30A [131]
were in agreement with the presence of proliferating
cells in CRPC. Of particular interest is that we observed
a transcript anti-sense to NKX3-1, a tumor suppressor,
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were AS and CR, but not RAD. Anti-sense transcription
m a yh i n d e rg e n ee x p r e s s i o nf r o mt h eo p p o s i n gs t r a n d ,
and therefore, represents a novel mechanism by which
NKX3-1 expression may be silenced. There were also
some inconsistencies including the expression trends of
BTG1 [132], FGFRL1 [133], and PCOTH [134] and
that may be associated with non-cycling cells. Overall,
there was more support at the transcriptome level for
proliferation than not, which was consistent with
increased proliferation observed in the LNCaP Hollow
Fiber model [21].
Gene expression trends of GLO1 [135], S100A10 [136],
TRPM8 [137], and PI3KCD [138] suggest cell survival
pathways are active following androgen-deprivation and/
or in CRPC, while gene expression trends of CAMK2N1
[139], CCT2 [140], MDK [141,142], TMEM66 [143], and
YWHAQ [136] may oppose such suggestion. Taken
together, these data neither agree nor disagree with the
activation of survival pathways in CRPC. In contrast to
earlier reports in which MDK gene and protein expression
was determined to be higher in late stage cancer [63,142],
we observed a drop in the levels of MDK mRNA in CRPC
versus RAD. MDK expression is negatively regulated by
androgen [65]. Therefore, the decreased levels of MDK
mRNA in CRPC may suggest that the AR is reactivated in
CRPC.
Other
The significance of the gene expression trends of
AMD1, BNIP3, GRB10, MARCKSL1, NGRAP1, ODC1,
PPP2CB, PPP2R1A, SLC25A4, SLC25A6,a n dWDR45L
that function in cell growth or cell death/survival were
not straightforward. For example, BNIP3 and WDR45L,
both relatively highly expressed in CRPC versus RAD,
may be associated with autophagy. BNIP3 promotes
autophagy in response to hypoxia [144], and the
WDR45L-related protein, WIPI-49, co-localizes with the
autophagic marker LC3 following amino acid depletion
in autophagosomes [145]. It is not known if BNIP3 or
putative WDR45L-associated autophagy results in cell
survival or death. Levels of expression of NGFRAP1
were increased in CRPC versus RAD. The protein pro-
duct of NGFRAP1 interacts with p75 (NTR). Together
they process caspase 2 and caspase 3 to active forms,
and promote apoptosis in 293T cells [146]. NGFRAP1
requires p75 (NTR) to induce apoptosis. However,
LNCaP cells do not express p75 (NTR), and so it is not
clear if apoptosis would occur in this cell line [147].
Overall, genes involved in cell growth and cell death
pathways were altered in CRPC. Increased tumor bur-
den may develop from a small tip in the balance when
cell growth outweighs cell death. Unfortunately, the
contributing weight of each gene is not known, making
predictions difficult based on gene expression alone of
whether proliferation and survival were represented
more than cell death in this model of CRPC. It should
be noted that LNCaP cells are androgen-sensitive and
do not undergo apoptosis in the absence of androgens.
The proliferation of these cells tends to decrease in
androgen-deprived conditions, but eventually with pro-
gression begins to grow again mimicking clinical CRPC.
Conclusion
Here, we describe the LNCaP atlas, a compilation of
LongSAGE libraries that catalogue the transcriptome of
human prostate cancer cells as they progress to CRPC
in vivo. Using the LNCaP atlas, we identified differential
expression of 96 genes that were associated with castra-
tion-recurrence in vivo. These changes in gene expres-
sion were consistent with the suggested model for a role
of the AR, steroid synthesis and metabolism, neuroendo-
crine cells, and increased proliferation in CRPC.
Additional material
Additional file 1: Supplementary Figures. Figure S1: qRT-PCR analysis
of KLK3 gene expression during hormonal progression of prostate cancer
to castration-recurrence. RNA samples were retrieved from the in vivo
LNCaP Hollow Fiber model at different stages of cancer progression that
were: AS, androgen-sensitive, day zero (just prior to surgical castration
and 7 days post-fiber implantation); RAD, responsive to androgen-
deprivation, 10 days post-surgical castration; and CR, castration-recurrent,
72 days post-surgical castration. MNE, mean normalized expression,
calculated by normalization to glyceraldehyde-3-phosphate (GAPDH).
Error bars represent ± standard deviation of technical triplicates. Each
mouse represents one biological replicate. Figure S2: Ten K-means
clusters are optimal to describe the expression trends present during
progression to castration-recurrence. K-means clustering was conducted
over a range of K (number of clusters) from K = 2 to K = 20 and the
within-cluster dispersion was computed for each clustering run and
plotted against K. The within-cluster dispersion declined with the
addition of clusters and this decline was most pronounced at K = 10.
The graph of within cluster dispersion versus K shown here is for mouse
13N, but the results were similar for mice 15N and 13R. Figure S3: Trend
legend for Table 4. Gene expression trends of LongSAGE tags that
consistently and significantly altered expression in CR prostate cancer are
represented graphically with trends labeled A-P. * Statistics according to
the Audic and Claverie test statistic (p ≤ 0.05).
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